Phage display identification of MCR-1-targeting nanobodies to restore colistin susceptibility

The spread of antimicrobial resistance among gram-negative bacilli, particularly within Enterobacteriaceae and non-fermentative gram-negative bacilli, poses a serious and escalating threat to global public health. Colistin, a cationic antimicrobial peptide, remains a last-line treatment for infections caused by multidrug-resistant gram-negative bacteria. However, the global dissemination of the plasmid-encoded colistin resistance gene mobilized colistin resistance-1 ( mcr-1 ) has contributed to increasing cases of colistin resistance and threatens global health. Nanobodies offer advantages, including high affinity, stability, and small size. Here, we isolated anti-MCR-1.1 nanobodies from a phage-display library and evaluated their potential to restore colistin efficacy. The periplasmic catalytic domain of MCR-1.1 was purified by affinity chromatography and used to immunize alpacas, resulting in the construction of a phage-displayed nanobody library against MCR-1.1 with a size of 5.8 × 10⁸ CFU. After biopanning, several anti-MCR-1.1 nanobodies specific for the periplasmic catalytic domain of MCR-1.1 were successfully isolated. Among them, high-affinity nanobodies Nb7, Nb12, Nb24, and Nb30 were selected in vitro , with Nb30 demonstrating promising activity. Following engineering, the Nb30-1 variant was generated and shown to exhibit enhanced efficacy. In combination with colistin, Nb30-1 effectively inhibited the growth of colistin-resistant, MCR-1.1-expressing laboratory Escherichia coli BL21(DE3), as determined by the growth dynamics curve. Molecular docking analysis revealed the binding interactions between Nb30/Nb30-1 and the MCR-1.1 protein, and affinity measurements confirmed their high binding affinity for the MCR-1.1 antigen. Given the exquisite conservation of key catalytic residues and the epitope recognized by Nb30-1 across MCR-1 variants, Nb30-1 represents a promising macromolecular adjuvant strategy to overcome MCR-1-mediated resistance. IMPORTANCE The escalating use of antibiotics has driven a global rise in antibiotic resistance, underscoring an urgent need for adjuvants that can restore the susceptibility of drug-resistant bacteria. In this study, we isolate anti-MCR-1 nanobodies from a phage-display library and evaluate their potential to restore colistin efficacy. Following engineering, the Nb30-1 variant was generated and shown to exhibit enhanced efficacy. These findings suggest that engineered anti-MCR-1 nanobodies, particularly Nb30-1, represent a promising therapeutic strategy to combat MCR-1-positive colistin-resistant bacterial infections by resensitizing bacteria to colistin.

Authors

Institutions

Publication Details

Journal
Microbiology Spectrum
Published
2026-11-18
DOI
https://doi.org/10.1128/spectrum.01904-26
Primary Topic
Antibiotic Resistance in Bacteria
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Phage display identification of MCR-1-targeting nanobodies to restore colistin susceptibility

Chenyu Lou, Lanjie Ren, Manping Gu, Li Zhang et al.
1 links
Microbiology Spectrum
Antibiotic Resistance in Bacteria
article

Phage display identification of MCR-1-targeting nanobodies to restore colistin susceptibility

Chenyu Lou, Lanjie Ren, Manping Gu, Li Zhang, Qiming Li, Yajie Zhao, Suxia Wu, Liang Zhao, Xu Zhang
article en

Abstract

The spread of antimicrobial resistance among gram-negative bacilli, particularly within Enterobacteriaceae and non-fermentative gram-negative bacilli, poses a serious and escalating threat to global public health. Colistin, a cationic antimicrobial peptide, remains a last-line treatment for infections caused by multidrug-resistant gram-negative bacteria. However, the global dissemination of the plasmid-encoded colistin resistance gene mobilized colistin resistance-1 ( mcr-1 ) has contributed to increasing cases of colistin resistance and threatens global health. Nanobodies offer advantages, including high affinity, stability, and small size. Here, we isolated anti-MCR-1.1 nanobodies from a phage-display library and evaluated their potential to restore colistin efficacy. The periplasmic catalytic domain of MCR-1.1 was purified by affinity chromatography and used to immunize alpacas, resulting in the construction of a phage-displayed nanobody library against MCR-1.1 with a size of 5.8 × 10⁸ CFU. After biopanning, several anti-MCR-1.1 nanobodies specific for the periplasmic catalytic domain of MCR-1.1 were successfully isolated. Among them, high-affinity nanobodies Nb7, Nb12, Nb24, and Nb30 were selected in vitro , with Nb30 demonstrating promising activity. Following engineering, the Nb30-1 variant was generated and shown to exhibit enhanced efficacy. In combination with colistin, Nb30-1 effectively inhibited the growth of colistin-resistant, MCR-1.1-expressing laboratory Escherichia coli BL21(DE3), as determined by the growth dynamics curve. Molecular docking analysis revealed the binding interactions between Nb30/Nb30-1 and the MCR-1.1 protein, and affinity measurements confirmed their high binding affinity for the MCR-1.1 antigen. Given the exquisite conservation of key catalytic residues and the epitope recognized by Nb30-1 across MCR-1 variants, Nb30-1 represents a promising macromolecular adjuvant strategy to overcome MCR-1-mediated resistance. IMPORTANCE The escalating use of antibiotics has driven a global rise in antibiotic resistance, underscoring an urgent need for adjuvants that can restore the susceptibility of drug-resistant bacteria. In this study, we isolate anti-MCR-1 nanobodies from a phage-display library and evaluate their potential to restore colistin efficacy. Following engineering, the Nb30-1 variant was generated and shown to exhibit enhanced efficacy. These findings suggest that engineered anti-MCR-1 nanobodies, particularly Nb30-1, represent a promising therapeutic strategy to combat MCR-1-positive colistin-resistant bacterial infections by resensitizing bacteria to colistin.

Microbiology Spectrum
Henan University (CN), First Affiliated Hospital of Henan University (CN)
Health Commission of Henan Province, Natural Science Foundation of Henan Province
Good health and well-being
Antibiotic Resistance in Bacteria
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon